Stroke - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 593 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Stroke - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Stroke - Pipeline Review, H1 2016', provides an overview of the Stroke pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Stroke
- The report reviews pipeline therapeutics for Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Stroke therapeutics and enlists all their major and minor projects
- The report assesses Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Stroke

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Stroke
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 8
Stroke Overview 9
Therapeutics Development 10
Stroke - Therapeutics under Development by Companies 12
Stroke - Therapeutics under Investigation by Universities/Institutes 20
Stroke - Pipeline Products Glance 22
Stroke - Products under Development by Companies 26
Stroke - Products under Investigation by Universities/Institutes 35
Stroke - Companies Involved in Therapeutics Development 37
Stroke - Therapeutics Assessment 125
Drug Profiles 142
Stroke - Recent Pipeline Updates 403
Stroke - Dormant Projects 543
Stroke - Discontinued Products 558
Stroke - Product Development Milestones 562
Appendix 573

List of Tables

Number of Products under Development for Stroke, H1 2016 29
Number of Products under Development for Stroke - Comparative Analysis, H1 2016 30
Number of Products under Development by Companies, H1 2016 31
Number of Products under Development by Companies, H1 2016 (Contd..1) 32
Number of Products under Development by Companies, H1 2016 (Contd..2) 33
Number of Products under Development by Companies, H1 2016 (Contd..3) 34
Number of Products under Development by Companies, H1 2016 (Contd..4) 35
Number of Products under Development by Companies, H1 2016 (Contd..5) 36
Number of Products under Development by Companies, H1 2016 (Contd..6) 37
Number of Products under Development by Companies, H1 2016 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H1 2016 39
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 40
Comparative Analysis by Late Stage Development, H1 2016 41
Comparative Analysis by Clinical Stage Development, H1 2016 42
Comparative Analysis by Early Stage Development, H1 2016 43
Comparative Analysis by Unknown Stage Development, H1 2016 44
Products under Development by Companies, H1 2016 45
Products under Development by Companies, H1 2016 (Contd..1) 46
Products under Development by Companies, H1 2016 (Contd..2) 47
Products under Development by Companies, H1 2016 (Contd..3) 48
Products under Development by Companies, H1 2016 (Contd..4) 49
Products under Development by Companies, H1 2016 (Contd..5) 50
Products under Development by Companies, H1 2016 (Contd..6) 51
Products under Development by Companies, H1 2016 (Contd..7) 52
Products under Development by Companies, H1 2016 (Contd..8) 53
Products under Investigation by Universities/Institutes, H1 2016 54
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 55
Stroke - Pipeline by AB Science SA, H1 2016 56
Stroke - Pipeline by Acorda Therapeutics, Inc., H1 2016 57
Stroke - Pipeline by Acticor Biotech, H1 2016 58
Stroke - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2016 59
Stroke - Pipeline by Addex Therapeutics Ltd, H1 2016 60
Stroke - Pipeline by advanceCor GmbH, H1 2016 61
Stroke - Pipeline by Affibody AB, H1 2016 62
Stroke - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 63
Stroke - Pipeline by Anavex Life Sciences Corp., H1 2016 64
Stroke - Pipeline by Angion Biomedica Corp., H1 2016 65
Stroke - Pipeline by Antoxis Limited, H1 2016 66
Stroke - Pipeline by Aralez Pharmaceuticals Inc., H1 2016 67
Stroke - Pipeline by ArmaGen Inc., H1 2016 68
Stroke - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 69
Stroke - Pipeline by AstraZeneca Plc, H1 2016 70
Stroke - Pipeline by Athersys, Inc., H1 2016 71
Stroke - Pipeline by Bayer AG, H1 2016 72
Stroke - Pipeline by Bioasis Technologies Inc., H1 2016 73
Stroke - Pipeline by Biogen, Inc., H1 2016 74
Stroke - Pipeline by BioTime, Inc., H1 2016 75
Stroke - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 76
Stroke - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 77
Stroke - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2016 78
Stroke - Pipeline by D-Pharm Ltd., H1 2016 79
Stroke - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 80
Stroke - Pipeline by DiaMedica Inc., H1 2016 81
Stroke - Pipeline by Digna Biotech, S.L., H1 2016 82
Stroke - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 83
Stroke - Pipeline by Fina Biotech, H1 2016 84
Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016 85
Stroke - Pipeline by Glialogix, Inc., H1 2016 86
Stroke - Pipeline by Glucox Biotech AB, H1 2016 87
Stroke - Pipeline by Green Cross Corporation, H1 2016 88
Stroke - Pipeline by Grifols, S.A., H1 2016 89
Stroke - Pipeline by Huons Co., Ltd., H1 2016 90
Stroke - Pipeline by International Stem Cell Corporation, H1 2016 91
Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 92
Stroke - Pipeline by JN-International Medical Corporation, H1 2016 93
Stroke - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 94
Stroke - Pipeline by LegoChem Biosciences, Inc, H1 2016 95
Stroke - Pipeline by Living Cell Technologies Limited, H1 2016 96
Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2016 97
Stroke - Pipeline by M et P Pharma AG, H1 2016 98
Stroke - Pipeline by Mapreg S.A.S., H1 2016 99
Stroke - Pipeline by Mast Therapeutics, Inc., H1 2016 100
Stroke - Pipeline by Medestea Research & Production S.p.A., H1 2016 101
Stroke - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016 102
Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 103
Stroke - Pipeline by Neuralstem, Inc., H1 2016 104
Stroke - Pipeline by Neuren Pharmaceuticals Limited, H1 2016 105
Stroke - Pipeline by Neuronax SAS, H1 2016 106
Stroke - Pipeline by Neurotec Pharma SL, H1 2016 107
Stroke - Pipeline by NeuroVive Pharmaceutical AB, H1 2016 108
Stroke - Pipeline by New Haven Pharmaceuticals, Inc., H1 2016 109
Stroke - Pipeline by New World Laboratories, Inc., H1 2016 110
Stroke - Pipeline by NoNO, Inc., H1 2016 111
Stroke - Pipeline by Omeros Corporation, H1 2016 112
Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 113
Stroke - Pipeline by Pfizer Inc., H1 2016 114
Stroke - Pipeline by PharmatrophiX, Inc., H1 2016 115
Stroke - Pipeline by Pharmicell Co., Ltd., H1 2016 116
Stroke - Pipeline by Phoenix Biotechnology, Inc., H1 2016 117
Stroke - Pipeline by Phylogica Limited, H1 2016 118
Stroke - Pipeline by PhytoHealth Corporation, H1 2016 119
Stroke - Pipeline by Pluristem Therapeutics Inc., H1 2016 120
Stroke - Pipeline by Primary Peptides, Inc., H1 2016 121
Stroke - Pipeline by Q Therapeutics, Inc., H1 2016 122
Stroke - Pipeline by QR Pharma, Inc., H1 2016 123
Stroke - Pipeline by ReCyte Therapeutics, Inc., H1 2016 124
Stroke - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 125
Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016 126
Stroke - Pipeline by ReNeuron Group Plc, H1 2016 127
Stroke - Pipeline by SanBio, Inc., H1 2016 128
Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2016 129
Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2016 130
Stroke - Pipeline by StemCells, Inc., H1 2016 131
Stroke - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 132
Stroke - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 133
Stroke - Pipeline by SynZyme Technologies, LLC, H1 2016 134
Stroke - Pipeline by Targazyme, Inc., H1 2016 135
Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 136
Stroke - Pipeline by TikoMed AB, H1 2016 137
Stroke - Pipeline by vasopharm GmbH, H1 2016 138
Stroke - Pipeline by Vicore Pharma AB, H1 2016 139
Stroke - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016 140
Stroke - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016 141
Stroke - Pipeline by Xigen SA, H1 2016 142
Stroke - Pipeline by Zocere, Inc., H1 2016 143
Assessment by Monotherapy Products, H1 2016 144
Number of Products by Stage and Target, H1 2016 146
Number of Products by Stage and Mechanism of Action, H1 2016 153
Number of Products by Stage and Route of Administration, H1 2016 158
Number of Products by Stage and Molecule Type, H1 2016 160
Stroke Therapeutics - Recent Pipeline Updates, H1 2016 422
Stroke - Dormant Projects, H1 2016 562
Stroke - Dormant Projects (Contd..1), H1 2016 563
Stroke - Dormant Projects (Contd..2), H1 2016 564
Stroke - Dormant Projects (Contd..3), H1 2016 565
Stroke - Dormant Projects (Contd..4), H1 2016 566
Stroke - Dormant Projects (Contd..5), H1 2016 567
Stroke - Dormant Projects (Contd..6), H1 2016 568
Stroke - Dormant Projects (Contd..7), H1 2016 569
Stroke - Dormant Projects (Contd..8), H1 2016 570
Stroke - Dormant Projects (Contd..9), H1 2016 571
Stroke - Dormant Projects (Contd..10), H1 2016 572
Stroke - Dormant Projects (Contd..11), H1 2016 573
Stroke - Dormant Projects (Contd..12), H1 2016 574
Stroke - Dormant Projects (Contd..13), H1 2016 575
Stroke - Dormant Projects (Contd..14), H1 2016 576
Stroke - Discontinued Products, H1 2016 577
Stroke - Discontinued Products (Contd..1), H1 2016 578
Stroke - Discontinued Products (Contd..2), H1 2016 579
Stroke - Discontinued Products (Contd..3), H1 2016 580